Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Recruiting Not applicable

An Evaluation of Multisense® to Ensure a Safe Return Home Following High-risk Gastrointestinal Surgery, Compared With Standard Care.

NCT07552805 · tracked via the Priya Life Science France tracker
Sponsor
Rhythm Diagnostic Systems
Phase
Not applicable
Started
2026-06-16
Last updated
2026-09-09

Condition(s) studied

Reduction in the Initial Length of Stay

Investigational drug(s) / intervention(s)

Monitoring by MultiSense®

Monitoring by MultiSense®: The MultiSense device will be placed on the patient's back and will allow physicians to remotely monitor six biological parameters

Study summary

The SENSE-ECO study is a prospective, randomized trial of 490 high-risk patients designed to show that the MultiSense® remote monitoring patch safely reduces hospital stays following major digestive surgery. By continuously tracking vital signs for five days at home, the device aims to maintain clinical safety and quality of life while decreasing overall healthcare costs for the French medical system.

Eligibility

Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria : * Adults (aged 18 and over) * Patients scheduled for gastrointestinal surgery : * Major gastrointestinal cancer surgery (pancreas, liver, stomach, oesophagus, rectum) * Colorectal surgery (rectal resection, surgery on the rectum and anus other than rectal resection, minor or major surgery on the small intestine and colon) * Patients in non-critical care with a high risk of post-surgical complications (ASA score 2 or 3) * Patients who have a personal mobile phone and Wi-Fi connectivity at home * Patients who provide written informed consent to participate in the study * Patients who are members of or beneficiaries of a social security scheme * Patients who are proficient in French Exclusion Criteria : * Patients with a contraindication to the use of the device as described in the instructions for use (in particular: known skin allergy to adhesives or silicone, active implantable medical device such as a pacemaker or defibrillator, need for an MRI scan during the intended use of the device, intended application site of the device being tattooed, infected, ulcerated or damaged) * Any other condition which, in the investigator's opinion, would compromise the patient's safety or prevent compliance with the requirements of the protocol * Pregnant or breastfeeding patient * Adult under legal protection (under guardianship, curatorship or judicial protection) * Patient already participating in a clinical trial

Primary outcome measure(s)

  • Mean CCI score of the Detailed Complications Index, calculated on the basis of complications recorded according to the Clavien-Dindo classification over a 30 day postoperative period for each of the two groups: the MultiSense group and Standard group — 30 days
    The Clavien-Dindo classification is a system used in surgery to classify postoperative complications according to their severity
  • The average length of the initial stay for both groups — Up to 30 days

Trial sites (9)

FacilityCityRegionStatus
CHU de Nice Nice Alpes-Maritimes Not Yet Recruiting
CHU Saint-étienne Saint-Etienne Auvergne-Rhône-Alpes Not Yet Recruiting
La Sagesse Mutualist Clinic Rennes Brittany Region Not Yet Recruiting
CHU de Besançon Besançon Doubs Not Yet Recruiting
CHU Reims Reims Grand Est Not Yet Recruiting
GHND Bourgoin Isère Not Yet Recruiting
CHU Charles-Nicolle Rouen Seine-Maritime Not Yet Recruiting
CHU Amiens-Picardie Amiens France Not Yet Recruiting
Hôpital Cochin, AP-HP Centre Paris France Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07552805 on ClinicalTrials.gov ↗ ← All trials in France